ReviewBioinorganic chemistry and applications2018
An Overview of the Potential Therapeutic Applications of CO-Releasing Molecules.
Review in Bioinorganic chemistry and applications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Carbon monoxide-releasing molecule CORM-401 treatment elicits corticosterone-driven stress lipolysis and tissue-specific hypoxia-inducible factor activation.Redox biology · 2026Article
- Hydroxyflavone-Modified Aza-BODIPY Derivatives for Combined Photodynamic and CO Therapy against Neuroblastoma.Journal of medicinal chemistry · 2026Article
- Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- CORM-3 mitigates hypoxia/reoxygenation-induced injury in neonatal rat cardiomyocytes by regulating mitochondrial-mediated apoptosis and complex IV activity.Histology and histopathology · 2026Article
- Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential.Frontiers in immunology · 2026Review
- Carbon Monoxide and Prokaryotic Energy Metabolism.International journal of molecular sciences · 2025Review
- Recent advances in carbon monoxide-releasing nanomaterials.Bioactive materials · 2024Review
- Recent progress on anti-nociceptive effects of carbon monoxide releasing molecule-2 (CORM-2).Molecular and cellular biochemistry · 2024Review
- CORM-3 Inhibits the Inflammatory Response of Human Periodontal Ligament Fibroblasts Stimulated by LPS and High Glucose.Journal of inflammation research · 2024Article
- Potential effects of carbon monoxide donor and its nanoparticles on experimentally induced gastric ulcer in rats.Inflammopharmacology · 2023Article
- Near-infrared light triggered in situ release of CO for enhanced therapy of glioblastoma.Journal of nanobiotechnology · 2023Article
- Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).Molecular medicine reports · 2022Review
- Metal Complexes for Therapeutic Applications.Trends in chemistry · 2021Article
- The role of brain gaseous neurotransmitters in anxiety.Pharmacological reports : PR · 2021Review
- Carbon monoxide-triggered health effects: the important role of the inflammasome and its possible crosstalk with autophagy and exosomes.Archives of toxicology · 2021Review
- The Role of Gasotransmitters in Gut Peptide Actions.Frontiers in pharmacology · 2021Review
- Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials.Chemical reviews · 2020Article
- CORM-2-entrapped ultradeformable liposomes ameliorate acute skin inflammation in an ear edema modelActa pharmaceutica Sinica. B · 2020Article
- "CO"ping With a Sticky Situation.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- The role of host defences in Covid 19 and treatments thereof.Molecular medicine (Cambridge, Mass.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbon monoxide (CO) has long been known as the "silent killer" owing to its ability to form carboxyhemoglobin-the main cause of CO poisoning in humans. Its role as an endogenous neurotransmitter, however, was suggested in the early 1990s. Since then, the biological activity of CO has been widely examined via both the direct administration of CO and in the form of so-called "carbon monoxide releasing molecules (CORMs)." This overview will explore the general physiological effects and potential therapeutic applications of CO when delivered in the form of CORMs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.